Drugs / ABBV-321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03234712 | Oct 2017 → Apr 2021 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03234712 ↗ |
| Known as | Ser-T | “Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor...” PMID 36814898 ↗ Dec 2022 |
| Route | Intravenous | “administered via intravenous infusion” NCT03234712 ↗ |
| Target | EGFR | “directed against activated epidermal growth factor receptor (EGFR)” PMID 36814898 ↗ Dec 2022 |